On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Research shows routine follow-up misses most relapses in lymphoma patients in remission, highlighting the need for improved ...

Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T ...

Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within ...

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 and expect to initiate ...

XYF-19 is under clinical development by Xi'An Yufan Biotechnology and currently in Phase I for Diffuse Large B-Cell Lymphoma.

Panelists discuss the key challenges faced by patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis, how these challenges evolve during treatment, and the emotional and ...

High-dose therapy followed by autologous hematopoietic stem cell transplantation (auto-HCT) has become the treatment of choice for patients with relapsed aggressive non-Hodgkin lymphoma (NHL).